Acquisition of Trasir Therapeutics
Strategic Repositioning

Business Update – June 3, 2021

Forward-looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Auris Medical's need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Agenda

- Trasir Therapeutics acquisition
- RNA therapeutics landscape
- Oligonucleotide delivery
- OligoPhore™ platform
- Company repositioning
- Outlook

Acquisition of Trasir Therapeutics, Inc.

- Privately held, based in Tampa FL
- Pioneer in extrahepatic oligonucleotide delivery
- OligoPhore™ platform
- World-wide exclusive license from Washington University
- Triangular merger with Auris Medical Inc.
- Share-based transaction
- Transaction closed on June 1, 2021

Why Trasir Therapeutics?

- Review of strategic options initiated in fall 2020
  - Underappreciated development pipeline
  - AM-301 / Bentrio™ as catalyst
  - Need for fundamental changes
- Trasir Therapeutics most attractive option
  - Strong science / truly innovative / differentiated
  - Disruptive potential / high growth potential
  - Global market for RNA therapeutics > $1 billion in 2020
  - Investor familiarity with RNA delivery technology
  - Fit with own experience in cell-penetrating peptides
- Trasir Therapeutics looking for partner to translate cutting-edge science into therapeutics

Our vision for Trasir Therapeutics

Become leading company developing oligonucleotides for extrahepatic therapeutic targets

- Initiate the preclinical development of the first pipeline program (project code AM-401)
- Oncology and/or rare disease indication
- IND submission targeted for late 2022
- Explore further potential applications of OligoPhore™ platform for delivery of siRNA, mRNA and gene editing constructs
- Leverage platform's potential through strategic partnering

Oligonucleotide therapeutics landscape*

*list not exhaustive; does not include ASO companies

Our new CSO: Samuel Wickline, MD

- Founder and majority shareholder of Trasir Therapeutics
- Director of Health Heart Institute, Chair in Cardiovascular Medicine, Professor of Cardiovascular Sciences, Molecular Physiology and Pharmacology, and Medical Engineering at University of South Florida (USF)
- Professor of Medicine, Physics, Biomedical Engineering, and Cell Biology and Physiology at Washington University
- Funded continuously for 30+ years by NIH (~ $50 million)
- Author of > 300 research papers
- Holds > 50 issued or filed U.S. patent applications
- Founder of 2 other biotech startups

Current challenges in oligonucleotide delivery

- Current state-of-the-art for delivery of oligonucleotide therapeutics
  - Viral-based vectors
  - Lipid nanoparticles (LNPs)
  - Ligand conjugates
- Delivery technologies remain a key rate-limiting step for unlocking the potential of RNA therapeutics:
  - Viral based delivery vectors suffer from lack of transduction efficiency and target specificity
  - LNPs and currently available ligand conjugates using GalNac technology preferentially target the liver, and many have suboptimal therapeutic index

How OligoPhore™ works

Trasir's **peptide-based OligoPhore™** technology allows for safe and effective delivery of RNA payloads:

- *Stability*: siRNA complexed in nanoparticle format for, and only released inside of cells after uptake
- *Extrahepatic delivery*: not sequestered in liver, but permeates inflamed pathological tissues
- *Endosomal escape*: pH-dependent nanoparticle disassembly, followed by full release of siRNA into cytoplasm
- *Selectivity*: silences molecular targets in diseased tissues only
- *Safety*: no cellular or adaptive immune responsivity to nanoparticle components or siRNA after multiple serial doses, and no organ toxicities in mice

Stable peptide-siRNA polyplex formulation



ACS Nano. 2013. 10.1021/nn403311c

Summary of OligoPhore™ mechanism of action



Biotechnology Advances. 2015. 10.1016/j.biotechadv.2015.05.005
ACS Nano. 2013. 10.1021/nn403311c

Preclinical data from murine disease models (siRNA payloads)

- Pancreatic and colorectal cancer (KRAS)
- Ovarian cancer (TAM: AXL)
- Lung cancer (ETV-2)
- Metastatic Melanoma (NFkB)
- Adult T Cell Leukemia/Lymphoma (NFkB)
- Sarcoma (MYCT-1)
- Necrotizing enterocolitis (NFkB)
- Rheumatoid and osteoarthritis (NFkB)
- Atherosclerosis (JNK2)
- Metabolic syndrome/Obesity (ASXL2)
- Aortic Aneurysm (NFkB)

Key in vivo data from oncology models (siRNA delivery)

Effective knockdown of ETV-2 siRNA in Lewis Lung cancer model



JCI Insight. 2018. 10.1172/jci.insight.97349

KRAS siRNA for pancreatic tumor



Oncotarget. 2019. 10.18632/oncotarget.27109

OligoPhore™ delivering mRNA payloads

Osteoarthritis (ex vivo): WNT 16 mRNA transfection in human cartilage explants



Pharmaceutics. 2020. PMC7022671

Atherosclerosis (in vivo): p27^{Kip1} mRNA transfection in vascular smooth muscle cells (femoral artery wire injury)



Molecular Therapeutics. 2021. 10.1016/j.ymthe.2021.01.032

AM-401 development plan

- Initial development focus on siRNA applications
- Select therapeutic indication
- Favoring oncology and/or orphan drug indications
- Advance research on mRNA and other potential payloads
- Non-human primate pivotal toxicology study
- Team of in-house experts, complemented by network of consultants and CROs in EU and US

Reposition the Company

altamira therapeutics

RNA therapeutics
Systemic, local, Rx

altamira medica

Nasal spray – allergy and viral infection, OTC

Auris Medical
Cochlear therapies

Tinnitus, hearing loss
Local, Rx

- Focus on development of RNA therapeutics
- Spin off or divest existing assets in neurotology, rhinology and allergology
- Investors prefer “pure plays”
- Prepare for separation within 12-18 months
- Important milestones
- Aim to unlock and create significant shareholder value

Proposed change of company name

Auris Medical
Cochlear therapies

EARS

altamira
therapeutics

CYTO

Subject to approval by July 2021 Extraordinary General Meeting

Proposed new BoD member: Margrit Schwarz, PhD MBA

- 25 years of experience in biopharmaceutical R&D across multiple indications and modalities, incl. RNA delivery
- Multiple IND filings and one approved drug (Repatha)
- Leadership roles at Amgen, Boehringer Ingelheim, Roche, Genevant
- Universities of Muenster and Cologne (DE)
- UT Southwestern Medical Center, Dallas TX
- Columbia Business School, New York

Upcoming Milestones

Q2 2021	Launch AM-301 in selected markets
Q2 2021	Target indication for AM-401
Q3 2021	Submission 510(k) for AM-301
Q3 2021	Start Covid-19 trial with AM-301 in India
Q3 2021	Completion recruitment Part B AM-125 Ph2 trial
Q4 2021	Read-out Covid-19 trial
Q4 2021	Read-out from Part B AM-125 Ph2 trial
Q1 2022	IND AM-125 / AM-201
Q1 2022	Start AM-125 Ph3 trial


altamira
therapeutics